key: cord-0078735-qx1oxu1w
authors: Panarese, Alba
title: Endoscopic resection for early gastric cancer: Towards a global understanding
date: 2022-04-07
journal: World J Gastroenterol
DOI: 10.3748/wjg.v28.i13.1377
sha: d1bc74c3f85fe33c8c39094e2aa3383f7b372273
doc_id: 78735
cord_uid: qx1oxu1w

Gastric cancer is widespread globally, and disease diagnosis is accompanied by high mortality and morbidity rates. However, prognoses and survivability have improved following implementation of surveillance and screening programs, which have led to earlier diagnoses. Indeed, early diagnosis itself supports increased surgical curability, which is the main treatment goal and guides therapeutic choice. The most recent Japanese guidelines for endoscopic submucosal dissection and endoscopic mucosal resection for early gastric cancer consider the degree of endoscopic curability in relation to the characteristics of the gastric lesions. In clinical practice, the management approach for both prevention and treatment should be similar to that of colon lesions; however, unlike the established practices for colorectal cancer, the diagnostic and therapeutic pathways are not shared nor widespread for gastric cancer. Ultimately, this negatively impacts the opportunity to perform an endoscopic resection with curative intent.

Core Tip: Gastric cancer accounted for 5.6% of all new global cancer cases in 2020 and 7.7% of all cancer deaths. It's generally high mortality and morbidity rates highlight the need for early detection, to increase the curability of surgical treatment. In countries where gastric cancer screening programs exist, endoscopic curability is possible because gastroscopy with magnification and chromoendoscopy can detect gastric lesions at an early stage. It is necessary to support screening programs more widely to achieve the successful implementation of the common strategies of prevention, diagnosis and treatment, thereby reducing the incidence of advanced gastric cancer around the world. 

The review by Young et al [1] , which offers a broad overview of endoscopic diagnosis and treatment of gastric dysplasia and early cancer with the prospect of future implications, was received with great interest. The authors reported that endoscopic treatment of precancerous lesions and early gastric cancer reduces rates of advanced carcinoma and avoids the requirement for surgery. However, there are relevant differences between the East and West for data related to the practice of endoscopic resection and the histological definitions of lesions[1].

Gastric cancer accounts for a significant proportion of cancer-related morbidity and mortality worldwide [2, 3] , and early detection is required to reduce the rates of each. The risk of progression from low-grade and high-grade dysplasias detected by biopsy to gastric cancer is high. For this reason, guidelines suggest endoscopic removal of any dysplastic lesion [4, 5] . However, the incidence of early gastric cancer differs among countries, particularly for those in the Eastern and Western regions of the world [2, 3, 6] . In European countries, for example, early-stage gastric cancer accounts for less than 10% of diagnosed cases, which is much less than that in Asian countries where endoscopic screening is practiced. It has been reported that endoscopic screening may reduce the risk of death from gastric cancer without affecting gastric cancer incidence [7] . In fact, in the East, gastric cancer screening programs allow early diagnosis and consequently increase the curability of subsequent treatment by surgical resection. Likewise, endoscopic resection allows endoscopic curability, and through these collective clinical efforts, morbidity and mortality of gastric cancer can continue to decrease [3] .

Therefore, advances in endoscopic imaging and resection techniques as well as improved endoscopist training are very important. Yet the maximal benefits will only be realized if these efforts are carried out alongside expanded implementation of screening and surveillance gastroscopies because gastric cancer originates from precancerous lesions. Intriguingly, this pathogenic pattern is similar to that of colon cancer, whereby the cancer arises from polypoid and non-polypoid lesions of the colon [8] .

Our ongoing Italian multicenter prospective observational study on endoscopic submucosal dissections of early gastric cancer has, so far, enrolled 32 cases in 18 mo in 12 centers. A comparison with other studies is not possible at this time for several reasons, namely among them unavoidable alterations to the clinical routine caused by the coronavirus disease 2019 pandemic. However, it appears that in addition to technological and diagnostic advances and improved skills of endoscopists, the presence of screening programs could be important to further identify and enroll patients who are atrisk. This represents a similar trend to that experienced in the colon cancer screening programs.

The ongoing high incidence of gastric cancer, especially in the youngest generations, due to the persistent spread of Helicobacter pylori (H. pylori) infection, makes gastric cancer a major public health challenge. Currently, the mortality rate for total gastric cancer deaths is higher than that of either breast cancer or colon cancer [3, 9] . Since it is important to achieve a common vision for eradicating H. pylori on a global scale, the additional application of both H. pylori antibody titer and pepsinogen levels together may further promote the effectiveness of gastric cancer screening programs [10] .

The new Japanese Guidelines for Endoscopic Submucosal Dissection and Endoscopic Mucosal Resection for Early Gastric Cancer (Second Edition)[11] define the indications for endoscopic treatment in relation to curability and according to the risk of lymph node metastases, based on current scientific evidence. Absolute, expanded and relative indications for the endoscopic treatment of gastric lesions and levels of curability ("endoscopic curability A: curative resection," "endoscopic curability B" and "endoscopic curability C")[11] are the starting point for prospective confirmatory studies in both Eastern and Western countries. These studies should determine the 5-year survival when these screening programs are implemented.

Endoscopic diagnosis and treatment of gastric dysplasia and early cancer: Current evidence and what the future may hold

Globocan 2020-Stomach Cancer

Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries

Long-term follow-up study of gastric adenoma/dysplasia

Gastric cancer risk in patients with premalignant gastric lesions: a nationwide cohort study in the Netherlands

The 5-year relative survival rate of stomach cancer in the USA

Endoscopic Screening in Asian Countries Is Associated With Reduced Gastric Cancer Mortality: A Meta-analysis and Systematic Review

The gastric precancerous cascade

Is gastric cancer becoming a rare disease

Gastric Cancer Screening by Combined Assay for Serum Anti-Helicobacter pylori IgG Antibody and Serum Pepsinogen Levels--The ABC Method

Guidelines for endoscopic submucosal dissection and endoscopic mucosal resection for early gastric cancer